100 results about "Treated animal" patented technology

The present disclosure relates to flavor compositions and pet food products for preventing and / or treating chronic kidney disease (CKD) and / or urinary tract disease in an animal. In certain embodiments, the flavor compositions and pet food products have enhanced palatability.

Provided in the present application are an isoxazoline compound as shown in formula (I), a pharmaceutical composition thereof, and the use thereof in the prevention or treatment of infestation or infection by animal parasites. The compound has excellent insecticidal and acaricidal activities against internal or external parasites of mammals, poultry or fishes.

The present invention relates to the technical field of veterinary medicinal products and specifically to a composition for the treatment of a skin disease in an animal. The main active ingredients of the composition are rapamycin, miconazole, and meloxicam in a mass ratio of (0.01–10):(0.1–20):(0.1–5) and a solvent mixture of water and polyethylene glycol in which the main active ingredients are soluble. The composition has considerable curative effects on fungal infections on the skin surfaces of animals, with low toxicity and minimal irritation.

The invention relates to a veterinary hoof disease prevention and treatment composition as well as a preparation method and application thereof, and aims to solve the technical problems that existing commercial hoof bath lotion is limited in sterilization effect and relatively strong in local irritation, and a safe and efficient treatment medicament for treating cow hoof warts is lacked and the like. The invention provides a veterinary composition which comprises the following active ingredients: a glycyrrhizic acid compound, didecyl methyl ammonium bromide and polyhexamethylene guanidine salt, and the three components are combined, so that the composition has an antibacterial effect and an effect of promoting skin tissue repair at the same time. A series of tests prove that the traditional Chinese medicine composition can effectively inhibit animal pathogenic bacteria, prevent and / or treat animal limb and foot diseases and promote healing and repairing of ulcer injury. The medicament disclosed by the invention is suitable for preventing and treating limb and hoof diseases in a large-scale pasture, has the characteristics of high sterilization efficiency, good safety and effective treatment, and can improve the animal hoof health management level.

The present invention provides a method for preparing a MXene-based flexible force-sensitive nonwoven sensing fabric, comprising: preparing a MXene solution, including dissolving MXene in deionized water to prepare the MXene solution; pre-treating animal hair to remove impurities on the surface of the animal hair; repeatedly coating the pre-treated animal hair with MXene and drying it to form MXene-coated animal hair fibers; further treating the MXene-coated animal hair fibers to obtain a flexible force-sensitive nonwoven sensing fabric to be encapsulated; self-encapsulating the flexible force-sensitive nonwoven sensing fabric using a felting method to obtain animal hair felt; and evenly laying pure animal hair fibers on the animal hair felt for post-processing to obtain a MXene-based flexible force-sensitive nonwoven sensing fabric. Also provided is a force-sensitive fabric sensor, including a MXene-based flexible force-sensitive nonwoven sensing fabric prepared using the MXene-based flexible force-sensitive nonwoven sensing fabric preparation method; and a typical application of the force-sensitive fabric sensor in physiological signal monitoring.

Embodiments described relate to a medical device including an invasive probe that, when inserted into an animal (e.g., a human or non-human animal, including a human or non-human mammal), may aid in diagnosing and / or treating a lesion of the animal (e.g., a growth or deposit within vasculature that fully or partially blocks the vasculature). The invasive probe may have one or more sensors to sense characteristics of the lesion, including by detecting one or more characteristics of tissues and / or biological materials of the lesion. The medical device may be configured to analyze the characteristics of a lesion and, based on the analysis, provide treatment recommendations to a clinician. Such treatment recommendations may include a manner in which to treat a lesion, such as which treatment to use to treat a lesion and / or a manner in which to use a treatment device.

The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, (I) wherein A1, A2, R1 and R2, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and / or treatment of an infection caused by pestivirus in an animal.

It is an object of the present invention to provide a composition for effectively preventing or treating Malassezia skin diseases.SOLUTION: The above problem can be solved by a composition for preventing or treating Malassezia dermatosis comprising citral of the present invention as an active ingredient, or a method for preventing or treating Malassezia dermatosis of an animal comprising a step of bringing an effective amount of citral into contact with the skin of an animal (excluding human).SELECTED DRAWING: None

The invention belongs to the field of biological pharmacy and animal medicine, and particularly relates to a nano antibody of antibacterial hair adhesin protein CfaE as well as a preparation method and application of the nano antibody. The invention provides a nano antibody mVHH-IgA of antibacterial hair adhesin protein CfaE, the nano antibody at least comprises a VHH fragment, the VHH fragment comprises three amino acid fragments of CDR1, CDR2 and CDR3, and the amino acid sequence of the CDR1-3 is shown as SEQ ID NO.1-3 in sequence, or the amino acid sequence of the CDR1-3 is shown as SEQ ID NO.4-6 in sequence, and the nano antibody mVHH-IgA of the antibacterial hair adhesin protein CfaE is prepared from the nano antibody mVHH-IgA of the antibacterial hair adhesin protein CfaE, the nano antibody mVHH-IgA of the antibacterial hair adhesin protein CfaE and the nano antibody mVHH-IgA of the antibacterial hair adhesin protein CfaE. Meanwhile, the VHH fragment is also fused with a secreting type IgA alpha chain constant region. The nano antibody mVHH-IgA provided by the invention has high specificity and stability, the nano antibody mVHH-IgA as a feed additive is mixed with a conventional feed to feed animals, and animal experiments show that the animal bacterial diarrhea can be effectively treated by feeding the feed containing the nano antibody mVHH-IgA provided by the invention.

The disclosure relates to compositions and methods of bacterial species expressing endolysins for the prophylaxis and treatment of methanogen growth in the digestive tract of an animal. More specifically, the disclosure relates to agents, compositions, and methods for preventing and / or inhibiting growth of methanogens.

There are provided a composition for preventing and treating heart disease due to pulmonary hypertension, and a functional preparation containing the same. The composition includes pimobendan, enalapril, torsemide, and spironolactone, and is thus effective in preventing and treating heart disease and pulmonary hypertension of animals.

The present invention relates to a composition for animals comprising a combination of one, two or more acid components and a binder. The binding agent comprises a tannin component and / or a polygalactose component. Further, the present invention relates to a composition for use as a pharmaceutical alternative, and in particular for use in the prevention and / or treatment of diarrhea in an animal. The invention also relates to the use of said composition for reducing the use of antibiotics and / or zinc oxide in animal breeding.

This application relates to compositions and methods used to treat animals with at least one microbial protein, such as a flagellin protein. In embodiments, application relates to compositions and methods to treat animals with a fusion protein comprising at least one adjuvant protein, such as a flagellin protein. In embodiments, the composition further includes at least one adjuvantic protein fused with at least one antigen protein, and the fusion protein is expressed in diatoms.

The disclosure relates to a sorting system for automatically selecting animals to be treated during a treatment period. A first aspect is a sorting system automatically selecting animals to be treated during a treatment period. The sorting system includes an automatic sort gate and a control arrangement receiving, via a user interface, user input indicative of sorting criteria applicable to animal properties and a maximum number of the animals allowed to be present simultaneously in the sorting area. The control arrangement is further configured to monitor a number of animals that enter and exit the sorting area. The control arrangement is finally configured to adjust one or more parameter values of the one or more sorting criteria, based on the monitored number of animals that enter and exit the sorting area. The disclosure also relates to a corresponding method and to a computer program for performing the method.

The present invention relates to a composition comprising a mixture of empty liposomes, wherein the mixture of empty liposomes comprises: (a) a first empty liposome comprising cholesterol, wherein the amount of cholesterol is at least 30% (weight / weight); and (b) a second empty liposome comprising sphingomyelin, the composition being useful for treating sepsis, severe sepsis, septic shock or prolonged and severe hypotension, preferably sustained hypotension, in animals, preferably humans, for treating hypotension, preferably such sustained hypotension, in septic shock, sepsis, severe sepsis, acute respiratory distress syndrome or acute lung injury in animals, preferably humans, or for treating toxic shock syndrome in animals, preferably humans.

The present invention discloses the use of dehydroandrographolide in synergistic effect with polymyxin B in the preparation of a drug for treating Gram-negative bacterial infections. The Gram-negative bacteria include Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Salmonella. The present invention also discloses an antibacterial combination ratio of dehydroandrographolide and the antibiotic polymyxin B, as well as an optimal ratio for treating animal infections. This invention provides a new therapeutic strategy for the clinical treatment of bacterial infectious diseases.

This invention relates to a combination, such as a composition, and its therapeutic and prophylactic uses. In particular (although not exclusively) the invention relates to a new method to modulate or treat the microbiome of an animal through selectivity towards microorganisms using proteins, such as lactoperoxidase. More particularly the invention relates to a new method to modulate or treat the oral cavity microbiome of a canine animal.

The invention provides a prevention and control method for cynomolgus monkeys based on SRV virus detection, and belongs to the technical field of cynomolgus monkey SRV virus detection, the cynomolgus monkeys after birth are subjected to intensive SRV antigen PCR and SRV antibody ELISA detection and are fed and managed in groups, negative animals after 9 months are subjected to annual quarantine, positive animals stop quarantine and are subjected to positive management by default, and the cynomolgus monkeys after birth are subjected to SRV antigen PCR detection and SRV antibody ELISA detection by default. The antibody positive and / or antigen positive belongs to the positive category. According to the method, SRV antigen PCR and SRV antibody ELISA detection are densely carried out on the cynomolgus monkeys after birth, grouping feeding management is carried out, early prevention and control can cut off a transmission chain, recessive infection can be effectively recognized, partially-infected monkeys are low in antibody reaction and even cannot be detected, but long-term detoxification can be achieved, recessive infection sources can be accurately removed by combining PCR and serological detection in the baby monkey period, and the method has the advantages of high specificity, high sensitivity, high sensitivity and the like. Although the detection cost is invested in the early stage, huge losses such as treatment, animal elimination and experiment repetition caused by disease outbreak in the future can be avoided.

The present disclosure provides veterinary formulations comprising rapamycin or rapalogs for administration to companion animals and methods of using the formulations to treat cardiac dysfunction, including hypertrophic cardiomyopathy, dilated cardiomyopathy, mitral valve disease, pressure-overload cardiac hypertrophy, cancer, effects of aging, inflammatory disease, and viral infection.

The invention relates to a drug composition for use in the treatment of diarrhea in animals, comprising a microbial enzyme solution, St. John's wort tea, vitamin B1, vitamin B6 and sodium benzoate as a preservative.

Avian necrotic enteritis (NE) is a complex and multifactorial enteric disease of commercial chickens and turkeys that has major economic consequences on the poultry industry worldwide. There is thus a need for improved and efficient vaccines for the prevention of diseases associated to pathogenic Clostridium perfringens in the poultry industry. The present application discloses immunogenic polypeptides unique to pathogenic strains of Clostridium perfringens which causes avian NE, as well as vaccine compositions comprising one or more of the immunogenic polypeptides, immunogenic fragments thereof, or nucleic acids encoding such immunogenic polypeptides and fragments. Methods and uses of the vaccine compositions for inducing or eliciting an immune response against Clostridium perfringens, for preventing or treating infection by Clostridium perfringens, and / or for preventing or treating avian NE in an animal, such as a poultry, are also disclosed.

The present application relates to the field of animal treatment technology, and in particular, to a nitric oxide treatment apparatus for preventing and treating an animal disease. The apparatus comprises a nitric oxide generator, a timer, a control module, a power supply module, an airflow control module, and an animal accommodation chamber. When a timing value of the timer reaches a target value, the airflow control module and the nitric oxide generator are activated. The airflow control module controls air to enter the nitric oxide generator from an air inlet. A high-voltage electrode and a counter electrode of the nitric oxide generator generate an electric field under the voltage applied by the power supply module, and the electric field ionizes the air to generate thermal plasma. The thermal plasma enters the animal accommodation chamber through an opening in the animal accommodation chamber, and thereby achieves the prevention and treatment of a disease in a living animal in the animal accommodation chamber. The device has the advantages of on-demand administration of nitric oxide, portability, no residue, and the production of additional sterilizing and disinfecting agents, and can be used for various small animals with improved efficacy in preventing and treating animal diseases.

The present invention relates to a composition comprising a mixture of empty liposomes wherein the mixture of empty liposomes comprises: (a) a first empty liposome comprising cholesterol wherein the amount of cholesterol is at least 30% (weight / weight); and (b) a second empty liposome comprising sphingomyelin, for use in the treatment of sepsis, severe sepsis, septic shock or long-term and severe hypotension, preferably persistent hypotension, in an animal, preferably a human, for use in the treatment of hyperlipidemia in an animal, preferably a human. The present invention relates to a pharmaceutical composition for treating toxic shock syndrome in animals, preferably humans, or to the treatment of toxic shock syndrome in animals, preferably humans, or to the treatment of hypotension in acute lung injury, preferably said persistent hypotension, or to the treatment of toxic shock syndrome in animals, preferably humans, preferably septicaemia, severe septicaemia, acute respiratory distress syndrome, or to the treatment of hypotension in acute lung injury, preferably said persistent hypotension.

The present invention relates to topical pharmaceutical compositions comprising a corticosteroid and an insecticide selected from pyrethrin or a synthetic pyrethroid insecticide. Methods for their use in the treatment of allergic dermatitis, particularly hypersensitivity to insect bites, in animals using the compositions of the invention are also described.

The present disclosure is directed to a polycell for forming a dosage projectile suitable for administering a biologically active agent to an animal remotely, the polycell comprising a first component having a semispherical shell formed from a polymer and a structural agent; a second component having a semispherical shell formed from a polymer and a structural agent; and a filling port in the first component or the second component; wherein the first and second components when joined form a polycell having a substantially spherical hollow body adapted to receive an agent to treat an animal. The present disclosure is also directed to a dosage projectile comprising an agent to treat an animal sealed in a polycell.